Brunswick Corporation vs Bristol-Myers Squibb Co — how do they compare? Brunswick Corporation trades at $79.77 (market cap $5.28B), while Bristol-Myers Squibb Co trades at $63.78 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co is far larger — about 24.6× Brunswick Corporation's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BC | BMY | |
|---|---|---|
Market Cap | $5.28B | $129.94B |
Sector | Consumer Cyclical | Health |
52-Week High | $89.22 | $65.89 |
52-Week Low | $58.75 | $42.60 |
Enterprise Value | $7.28B | $163.92B |
Dividend Yield | 2.16% | 3.96% |
Signals from Pluang's Aura AI — not financial advice
Brunswick Corporation (BC) trades at $79.54, down 1.11% on the day, with strong analyst support showing 22 buy ratings and a consensus price target of $85.33. Recent Q2 2026 earnings beat expectations with $1.56 EPS versus $1.19 expected, though the company posted a net loss of $137.3 million in 2025. Technical indicators show a bullish trend with support at $80 and resistance at $82, while fundamentals reveal mixed profitability with negative margins but positive cash flow from operations of $562.1 million.
The outlook remains cautiously optimistic given strong institutional backing and recent earnings beats, though investors face risks from negative profit margins and elevated P/E ratio of 73.92. The stock offers potential upside to analyst targets but requires monitoring of profitability improvements and debt management amid competitive pressures in the marine industry.
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
Trailing returns across standard periods
Latest headlines on both assets
Brunswick Corp is the leader in several recreational sectors. The firm is the leading boat manufacturer, and its brands include Mercury and Mariner outboard engines
Read more on BC →Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →